How can the elevated per particle atherogenicity of Lp(a) be explained? Is there heterogeneity among Lp(a) particles with the same isoform in the same individual? If outcomes trials of Lp(a) lowering agents are positive, which patients are most likely to benefit? These are the key questions considered by Lp(a) Forum Co-Chair, Professor John Chapman, in his presentation.
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.